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Abstract Electron microscopy of dimeric and trimeric single
chain antibody Fv fragments (scFvs) complexed with anti-
idiotype Fab fragments was used to reveal the orientation of
antigen binding sites. This is the first structural analysis that
discloses the multivalent binding orientation of scFv trimers
(triabodies). Three different scFv molecules were used for the
imaging analysis; NC10 scFv-5 and scFv-0, with five- and zero-
residue linkers respectively between the VH and VL domains,
were complexed with 3-2G12 anti-idiotype Fab fragments and
11-1G10 scFv-0 was complexed with NC41 anti-idiotype Fab
fragments. The scFv-5 molecules formed bivalent dimers
(diabodies) and the zero-linker scFv-0 molecules formed trivalent
trimers (triabodies). The images of the NC10 diabody-Fab
complex appear as boomerangs, not as a linear molecule, with a
variable angle between the two Fab arms and the triabody-Fab
complexes appear as tripods.
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1. Introduction
Recombinant single chain Fv fragments (scFvs), in which
the two variable domains are covalently joined via a £exible
peptide linker, have been shown to fold in the same confor-
mation as the Fv domain of the parent antibody [1,2]. ScFvs
with linkers greater than 12 residues in length can form stable
monomers which usually exhibit a similar antigen binding
a⁄nity to the parent antibody [1,3]. Reduction of the linker
length (to 2^12 residues) prevents pairing of VH and VL do-
mains on the same chain to form an Fv monomer and forces
pairing with complementary domains of another chain to
form bivalent dimers, termed diabodies [4^8]. The ¢ve-residue
linker sequence usually chosen for diabodies, Gly4Ser, was
originally designed as a £exible and hydrophilic hinge [4].
Further reduction of the linker length to fewer than two res-
idues, including direct ligation of the C-terminal residue of VH
to the N-terminal residue of VL, results in the formation of
trivalent trimers, termed triabodies [8^10]. Models of diabod-
ies with ¢ve-residue linkers (scFv-5, [5]) and triabodies (scFv-
0, [8^10]) have con¢rmed that signi¢cant £exibility between
Fv domains is possible, resulting in di¡erent relative orienta-
tions of the antigen binding sites. A model of scFv-0 mole-
cules as a diabody revealed the structure was severely con-
strained [4] and incompatible with the crystal structure of
an scFv-5 diabody [6]. We have now demonstrated, in two
cases [8,9], that trivalent trimers (triabodies) are the preferred
association of scFv-0 molecules with directly linked VH-VL
domains. We have proposed that the propensity to trimerise
is a general property of scFv-0 molecules constructed by direct
ligation of VH and VL domains [8,9]. Our understanding of
£exibility and binding site orientation in triabodies is based to
date on only one modelling study of a trivalent trimer [8] and
one crystal structure of an inactive VH-VL trimer [10]. Flexi-
bility between the antigen binding sites of scFv dimers and
trimers is an important aspect in the design of cross-linking
molecules for either cell recruitment immunotherapy [5] or
whole blood diagnostic applications [7]. Furthermore, the
increase in functional a⁄nity (avidity) for multivalent
scFvs [8] is dependent on the ability to simultaneously bind
adjacent antigens. Flexibility is obviously an important
factor in the ability to bind simultaneously to surface recep-
tors on the same cell. To characterise the £exibility and ori-
entation of the antigen binding sites in diabodies and triabo-
dies, we pre-formed stable molecular complexes with the
corresponding anti-idiotype Fab fragment and revealed their
low-resolution structure by single-molecule imaging. Fab
fragments were expected to appear as relatively rigid, linear
arms extending outwards from the antigen binding sites
[11,12].
2. Materials and methods
2.1. Construction of NC10 and 11-1G10 scFv genes
The VH and VL genes were ampli¢ed by PCR from the parent
NC10 [13] and 11-1G10 [14] hybridomas and scFvs were constructed
by PCR overlap extension. NC10 scFv-5 was constructed using a
Gly4Ser ¢ve-residue linker [8] and the scFv-0 genes were constructed
by ligation between codons for C-terminal VH-Ser112 and N-terminal
VL-Asp1 for NC10 and between C-terminal VH-Ser113 and N-terminal
VL-Gln1 for 11-1G10. Residues are numbered according to the Kabat
nomenclature as described [1]. The NC10 scFv genes were cloned into
the expression vector pPOW as described previously [8], whereas the
11-1G10 scFv gene was expressed in vector pGC as described [9].
Both pPOW and pGC vectors provide an N-terminal pelB leader
sequence and C-terminal FLAG octapeptide tag tail [8,9]. The entire
DNA sequences of the cloned scFv inserts were determined using
DNA puri¢ed by alkaline lysis and sequencing reactions performed
using the PRISM Cycle Sequencing Kit (ABI).
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2.2. ScFv synthesis, puri¢cation and formation of complexes with Fab
fragments
The NC10 scFv-5 and scFv-0 genes in pPOW were expressed [13]
and the proteins recovered from insoluble periplasmic aggregates by
denaturation, refolding in vitro and puri¢ed by a⁄nity and size ex-
clusion chromatography as described previously [8]. Puri¢ed scFvs
were concentrated to V1^2 mg/ml, dialysed against phosphate-bu¡-
ered saline (PBS), pH 7.4 which contained 0.02% (w/v) sodium azide
and stored frozen.
The 11-1G10 scFv-0 gene in pGC was expressed as a soluble pro-
tein and puri¢ed from the culture supernatant by a⁄nity chromatog-
raphy on an NC41 Fab Sepharose 4B a⁄nity column as described [9].
11-1G10 scFv-0 was concentrated to V1 mg/ml, dialysed against
TBS, pH 7.4 and stored at 4‡C.
The a⁄nity puri¢ed scFv molecules were fractionated by size ex-
clusion FPLC on either a Superdex 75 column (HR10/30) or a Super-
ose 12 column (HR 10/30, Pharmacia) in PBS to determine their
molecular size and to remove higher molecular mass aggregates and
any Fv monomers produced by proteolysis in the scFv-0 preparations
[8]. The concentrations of the scFv fragments were determined spec-
trophotometrically using the values for the extinction coe⁄cient
(O0:1%) at 280 nm of 1.73 and 1.75 for NC10 scFv-5 and scFv-0,
respectively, and of 2.03 for 11-1G10 scFv-0 calculated from the pro-
tein sequences [15].
The monoclonal antibodies NC41 (an IgG2a, anti-idiotype to 11-
1G10) and 3-2G12 (an IgG1, anti-idiotype to NC10) were isolated
from ascites £uid by protein A-Sepharose chromatography (Pharma-
cia). NC41 and 3-2G12 Fab fragments were prepared by proteolysis
of Ig and puri¢ed by gel ¢ltration on a Superdex 75 column (HR 10/
30) in PBS, pH 7.4, as described previously [8,16]. Complexes were
formed between scFv and anti-idiotype Fab as described [8,9] and
puri¢ed by size exclusion FPLC on a Superose 6 column (HR 10/
30) in PBS (£ow rate 0.5 ml/min) to remove unbound scFv or Fab.
2.3. Electron microscopy
Three complexes (NC10 scFv-5 diabody/Fab, NC10 scFv-0 triab-
ody/Fab and 11-1G10 scFv-0 triabody/Fab) and also a mixture of
NC10 scFv-0 triabody/Fab with free 3-G12 anti-idiotype Fab were
examined by electron microscopy. In each case, proteins were diluted
in PBS to concentrations of the order of 0.01^0.03 mg/ml. Prior to
dilution, 10% glutaraldehyde (Fluka) was added to the PBS to achieve
a ¢nal concentration of 1% glutaraldehyde. Droplets of V3 Wl of this
solution were applied to thin carbon ¢lm on 700-mesh gold grids
which had been glow-discharged in nitrogen for 30 s. After 1 min
the excess protein solution was drawn o¡, followed by application
and withdrawal of 4^5 droplets of negative stain (2% potassium phos-
photungstate adjusted to pH 6.0 with KOH). The grids were air-dried
and then examined at 60 kV in a JEOL 100B transmission electron
microscope at a magni¢cation of 100 000U. Electron micrographs
were recorded on Kodak SO-163 ¢lm and developed in undiluted
Kodak D19 developer. The electron optical magni¢cation was cali-
brated under identical imaging conditions by recording single mole-
cule images of the NC10 antibody (Fab) complex with its antigen,
in£uenza virus neuraminidase heads [17].
Measurements of particle dimensions were made on digitised micro-
graphs using the interactive facilities of the SPIDER image processing
suite [18] to record the coordinates of particle vertices. Particle arm
lengths and inter-arm angles were calculated from the coordinates for
229 diabodies and 114 triabodies.
3. Results
Three di¡erent scFv molecules were used for this study.
Two scFvs (scFv-5 and scFv-0) were derived from a parent
murine antibody NC10 with speci¢city to avian in£uenza vi-
rus N9 neuraminidase (NA). The molecular structure of this
neuraminidase and those of its complexes with NC10 Fab and
scFv have been determined to 2.5 Aî resolution by X-ray crys-
tallographic analysis [1,19]. The third scFv was derived from a
parent murine antibody 11-1G10, an anti-idiotype that com-
petes with the antigen, avian in£uenza virus N9 NA, for bind-
ing to murine NC41 antibody [20]. Protein chemical charac-
terisation has shown that the NC10 scFv-5 was a dimer
(diabody) [8] and that both scFv-0 molecules derived from
antibodies NC10 and 11-1G10 were trimers (triabodies) with
three active antigen combining sites [8,9]. The NC10 scFv-5
dimer and scFv-0 trimer used in this study were produced by
refolding from bacterial periplasmic inclusion bodies solubi-
lised in 6 M guanidine hydrochloride, while the 11-1G10 scFv-
0 trimer was recovered as an active, soluble molecule from the
culture supernatant by a⁄nity chromatography [9]. The mo-
lecular masses of isolated complexes between 3-2G12 anti-idi-
otype Fab and either NC10 scFv dimer or trimer con¢rmed
the stoichiometry of two 3-2G12 Fabs binding to the NC10
scFv-5 dimer and three 3-2G12 Fabs binding per NC10 scFv-
0 trimer (Fig. 1) [8]. These complexes were isolated by gel
¢ltration for imaging and were stable to dilution and freezing
(data not shown).
Electron micrographs of the NC10 scFv-5 diabodies com-
plexed with two anti-idiotype 3-2G12 Fab molecules
(MrW156 kDa) showed boomerang-shaped projections with
the angle between the two arms ranging from 60 to 180‡ (Fig.
2a, Fig. 3a). The mean angle was 122‡, with an approximately
normal distribution of angles about the mean (Table 1). Each
arm corresponds to a Fab molecule (Fig. 1) and, despite the
potential ‘elbow’ £exibility between Fv and C modules, ap-
pears as a relatively rigid, linear molecular rod which extends
outwards from the antigen binding sites [11,12]. Linearity of
the Fab arms under the current imaging conditions was con-
¢rmed by the appearance of free 3-2G12 anti-idiotype Fabs
imaged in conjunction with triabodies (data not shown). The
variation in the angle between the arms indicates that there
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Fig. 1. Schematic ‘static’ interpretation of scFv diabodies, triabodies
and their complexes with anti-idiotype Fab fragments. Ovals repre-
sent Ig V or C domains; the VH domains are shown shaded and
the N-terminal end of the scFv VH domain is marked with a dot.
(a) Rigid ‘back-to-back’ diabody [1] and (b) its linear Fab complex
with two-fold symmetry axis perpendicular to page. (c) Flexible
‘twisted’ diabody [6,10] and (d) its boomerang-shaped Fab complex
with vertical two-fold symmetry axis. (e) Triabody [8,9] and (f) its
Y-shaped Fab complex with three-fold symmetry axis perpendicular
to page. Fab molecules (g) are shown extending outwards from the
scFv antigen binding site and, obviously, other orientations of V-do-
main pairing and linker geometry in both diabodies and triabodies
are possible.
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appears to be considerable £exibility in the linker region join-
ing the two scFvs in the diabody.
In micrographs of NC10 scFv-0 triabodies complexed with
three 3-2G12 Fab molecules (MrW212 kDa), most ¢elds
showed a mixture of predominantly Y-shaped and V-shaped
projections (Fig. 2b). There was some variation in particle
appearance depending on the thickness of the stain on the
carbon ¢lm. The Y-shaped projections (Fig. 3b) were inter-
preted as tripods (viewed from above), which had adopted an
orientation in which all three legs (i.e. the distal ends of the
three Fab molecules) were in contact with the carbon ¢lm.
The three Fab legs were separated by two angles of mean
136‡ and one of mean 80‡. However, the range of angles
was such that for approximately 10% of particles the arms
were evenly spaced with angles all 120‡ ( þ 5‡). The Y-shaped
projections were unlikely to be planar as invariably one of the
Fab legs appeared foreshortened. The V-shaped projections
(Fig. 3c) were interpreted as tripods (triabody complexes)
lying on their sides on the carbon ¢lm, with two Fab legs
forming the V and the third Fab leg extending upward and
out of the stain which would account for the increase in
density sometimes observed at the junction of the V. The
V-shaped structures (Fig. 3c) were clearly di¡erent to
the boomerang-shaped diabody complexes (Fig. 3a), both
in the angle between Fab arms and in the projected density
in the centre of the molecules, consistent with the expected
models (Fig. 1). The interpretation of tripods lying on
their side is consistent with the appearance of a few
projections with all three Fab legs pointing in the same direc-
tion.
Images of the 11-1G10 scFv-0 triabody/NC41 Fab complex
were similar to the NC10 scFv-0 triabody/3-2G12 complex
with numerous Y-shaped tripods in which all three Fab
arms extended towards the same quadrant/direction (data
not shown). As before, many V-shaped projections showed
an increase in density at the junction of the V indicating a
FEBS 20059 3-4-98
Table 1
Histogram of inter-arm angles and lengths taken from 229 images of diabody-Fab complexes (NC10 scFv-5 complexed with 3-2G12 Fab)
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similar extension of the third leg of the tripod upward and out
of the stain.
4. Discussion
The imaging of the NC10 scFv-5 dimer complexed with two
anti-idiotype 3-2G12 Fabs revealed a planar boomerang-
shaped structure with two Fab arms extending from the dia-
body and with a variable angle of about 60^180‡ between Fab
arms with a mean of 122‡ (Fig. 2a). Few linear dimers (rods)
were observed (fewer than 5% of particles had angles greater
than 170‡), indicating that NC10 scFv-5 diabodies are un-
likely to form the rigid ‘back-to-back’ structure revealed in
the X-ray structure of crystals of the NC10 scFv-15 (mono-
mer) complexed to NA (Fig. 1b) [1]. Instead, the variable
angle observed between Fab arms in the boomerang-shaped
projections (Table 1) indicates there is considerable £exibility
in the linker region joining the two Fv structures. This orien-
tation is consistent with a ‘twisted’ or bent diabody structure
(Fig. 1d), similar to that modelled by Holliger et al. [4,5] and
con¢rmed in a crystal structure of a ¢ve-residue linker dia-
body [6]. However, in modelling studies of the L5MK16 dia-
body [5] the predicted angle between the Fv domains was
larger than 122‡ and ranged from 138‡ to 166‡.
The observed angle (Table 1) was interpreted as the true
angle between Fab arms lying £at on the support ¢lm and not
the result of variable orientations of Fab arms tilted out of the
plane of the ¢lm for the following reasons. Firstly, if one Fab
arm of the boomerang was £at on the support ¢lm, while the
other projected out of the plane of the ¢lm, the upwardly
projecting arm would appear foreshortened in projection com-
pared to the other arm. It would be expected that if the dis-
tribution of measurements of the longer arm of each particle
were compared with the distribution of measurements of the
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Fig. 3. Gallery of selected particles from electron micrographs of )a) boomerangs; NC10 scFv-5 diabody/3-2G12 Fab complex, (b) Y-shaped
tripods; NC10 scFv-0 triabody/3-2G12 Fab complex, (c) V-shaped projections; NC10 scFv-0 triabody/3-2G12 Fab complex. Staining and pho-
tography as for Fig. 2; magni¢cation bar 20 nm.
Fig. 2. Electron micrographs of complexes stained with potassium phosphotungstate (2%). Magni¢cation bar is 50 nm. a: NC10 scFv-5 diabod-
ies with two anti-idiotype 3-2G12 Fab molecules. The angle between the arms of the boomerang-shaped particles can be seen to vary from
about 60‡ to 180‡. b: NC10 scFv-0 triabodies with three 3-2G12 Fab molecules. Particles are predominantly either Y-shaped or V-shaped mo-
lecular complexes.
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shorter arm, the shorter arm measurements would show a
signi¢cantly greater standard deviation from the mean, due
to the e¡ect of varying angle of projection. However, it was
found that the standard deviation for the shorter arm lengths
was in fact smaller than that for the longer arm lengths (Table
1). Secondly, if the boomerangs were rigid, with a ¢xed Fab
arm angle but tilted out of the plane of the support ¢lm with
either the ends of the boomerang or the central point in con-
tact with the ¢lm, those molecules lying almost in the plane of
the ¢lm would appear to have the most acute inter-arm angle,
and the end-to-end length of the molecule would be greatest.
Also, those molecules oriented at right angles to the plane
would have more linear projections and the projected end-
to-end lengths would be shortest. However, a signi¢cant pro-
portion of the straightest particles were also among the lon-
gest measured, and there was only a weak negative correlation
between end-to-end length and angle (correlation coe⁄-
cient =30.33). Some variation in Fab arm length, even
when lying £at on the support grid, is expected due to staining
artifacts, radiation damage, and the e¡ects of negative stain
and dehydration on the protein.
The electron micrograph images (Figs. 2 and 3) of NC10
scFv-0 triabodies complexed with three 3-2G12 Fab molecules
showed that the three Fab arms of the trimer-Fab complex
are not coplanar, but are angled together in one direction and
appear as the legs of a tripod (Fig. 3b) consistent with the
triabody model of NC10 scFv-0 [8]. Similar Y-shaped tripod
structures were also clearly observed for the 11-1G10 scFv-0
triabody complexed with three NC41 Fab molecules (data not
shown). Triabodies are obviously £exible molecules, with ob-
served angles between Fab arms in the NC10 triabody-Fab
complexes distributed around two angles of mean 136‡ and
one of mean 80‡, and are not rigid molecules as shown sche-
matically in Fig. 1f. Numerous V-shaped images with an in-
creased density at the apex of the V were interpreted as the
third arm of the tripod pointing upwards (Fig. 3c). Since the
triabody-Fab complexes are stable in solution and all three
antigen combining sites have equivalent a⁄nity [8,9], it is un-
likely that one Fab leg has dissociated from the complex to
form the V-shaped projections. When free Fab arms were
imaged in a mixture with triabodies, they typically appeared
as distinctly linear rods of length comparable to that of tri-
abody arms (data not shown). It is highly unlikely that one
Fab arm had dissociated during preparation since imaging of
puri¢ed triabody preparations did not reveal free Fab mole-
cules in the proportion that would be anticipated: in fact few,
if any, such Fabs were observed. However, we cannot un-
equivocally rule out the possibility of some Fab dissociation
since the images of free Fab arms are at the limit of micro-
graph resolution.
In the construction of the NC10 scFv-0 molecule the VH C-
terminal residue Ser112 and the VL N-terminal residue Asp1
were ligated by direct fusion. While the absence of a £exible
linker in this construct presumably prevents the formation of
a dimer, the VH and VL domains paired to form a trimer.
Precise structural data, obtained by crystallographic analysis
[8,19], has shown that the C-terminal residue Ser112 is the last
constrained residue in the VH domain framework before the
start of the £exible hinge region and similarly, Asp1 of VL is
known to be hydrogen bonded to the V-domain framework
and is close to, but not involved in, the antigen binding re-
gion. Therefore, this zero-residue construct has no sites of
£exibility between the two domains. A computer graphic
model for the NC10 scFv-0 triabody, constructed using circu-
lar three-fold symmetry [8] and with VH and VL domains
rotated around the peptide bond to minimise steric clashes
between domains, showed that the Fv conformation and
CDR positions were consistent with a pyramid shaped mole-
cule. The three antigen binding sites are at the apices of the
pyramid; this would therefore produce a tripod structure
when complexed with three anti-idiotype Fab molecules
(Fig. 1), compatible with the Y-shaped projections observed
in the EM images (Fig. 3).
In the design of 11-1G10 scFv-0, an additional residue (VH-
Ser113) was present in the linker between VH and VL compared
to NC10 scFv-0. The zero-linker scFv-0 ‘diabody’ described
by Holliger et al. [4,5] also contained this additional residue.
The 11-1G10 scFv-0 exclusively formed trimers which were
shown to be fully active and trivalent for Fab binding [9]. It
is tempting to speculate that the trimeric conformation (tria-
bodies) will be preferred over dimers (diabodies) for other
scFv-0 molecules, although this property may be dependent
on the particular antibody chosen and the precise choice of
residues for the VH-VL linkage [8,9].
The gain in functional a⁄nity through multivalent binding
(often termed avidity [21]) makes trimeric scFvs attractive for
in vivo tumour imaging as an alternative reagent to diabodies
[22,23] and multivalent chemical conjugates [24^27]. The gain
in functional a⁄nity (avidity) for scFv trimers compared to
scFv monomers is due to apparently reduced o¡-rates which
result from both multiple binding and rebinding to the target
antigens [8,21]. Multiple binding to surface-bound antigens is
dependent on correct alignment and orientation in the Fv
modules of diabodies and triabodies. If multiple binding is
not sterically possible, particularly for surface-bound antigens,
then apparent gains in functional a⁄nity are likely to be small
and due only to the e¡ect of increased rebinding, which is
dependent on di¡usion rates and surface antigen concentra-
tion. Antigen orientation also a¡ects the ability of diabodies
and triabodies to simultaneously bind to multiple antigens on
a cell surface, and this factor is particularly important in the
design of any therapeutic reagent required to cross-link sur-
face receptors on either the same or adjacent cells [21,28].
Indeed, receptor cross-linking and enhanced cell activation
have recently been demonstrated using intact Ig molecules
conjugated together into £exible dimers [29]. Flexibility in
both scFv diabodies and triabodies is evident in our single
molecule imaging studies. The e¡ect of manipulating linker
length, sequence and structure on diabody and triabody
stability and £exibility can now be analysed using single mol-
ecule imaging of anti-idiotype complexes. The ability of tria-
bodies to cross-link surface receptors is unknown, and will
obviously depend on £exibility between the Fv modules and
the orientation of the antigen binding sites, as well as the
structure of the receptor. Furthermore, the construction of
tricistronic expression vectors should enable the production
of trispeci¢c scFv-0 trimers capable of cross-linking di¡erent
target antigens, with obvious applications in speci¢c cell re-
cruitment and activation.
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